New Virus-Immune cell combo targets Hard-to-Treat GI cancers
NCT ID NCT07544589
First seen Apr 26, 2026 · Last updated May 14, 2026 · Updated 5 times
Summary
This early-stage study tests a new treatment called DISP-10 for people with advanced colorectal, stomach, or esophageal cancers that have spread. The treatment combines a virus that may help the immune system attack cancer cells with specially engineered immune cells (CAR T cells). The main goals are to check safety and find the best dose, with 66 adults expected to take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.